Media

PHARMA SHOTS: Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies.

Wainberg ZA, Pant S, Weekes CD, et al.
Presented at the American Association for Cancer Research Special Conference in Cancer Research: Pancreatic Cancer
September 27-30, 2023
Boston, MA

PHARMA'S ALMANAC: At Elicio Therapeutics, we view real-world data and evidence (RWE) as a critical component for optimizing our drug development process –– particularly the design and execution of our AMPLIFY studies including patient selection and biomarkers of therapeutic response.

LAW 360: Clinical-stage biotechnology company Elicio Therapeutics Inc. said Monday it has chosen a longtime life sciences attorney to be its general counsel, overseeing the company's legal affairs as it continues its mission...

VANGUARDS OF HEALTH CARE PODCAST: Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains.

FIERCE Biotech: Interest in developing a vaccine for Epstein-Barr virus, or EBV, has grown as the link between infection and later consequences like multiple sclerosis and cancer has become clear.

PHARMA'S ALMANAC: Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer, Elicio Therapeutics. "As an oncologist, waiting with patients who’d undergone chemotherapy and surgery for mKRAS-driven tumors to see if they’d relapse left me feeling helpless — I wanted to do more than wait and see. "

ONCLIVE: Despite the high prevalence of KRAS mutations in pancreatic cancers, a limited number of cases harbor an actionable point mutation. Unlike other tumors where variants in KRAS, such as G12C, are more prominent, explorations into the more common subtypes in pancreatic cancer have begun to provide more guidance for therapeutic development as significant differences in survival outcomes come to light.